Eli Lilly Commits $40 Million to Indiana University for AI-Enhanced Clinical Trial Infrastructure
Key Insights
Eli Lilly and Company will provide up to $40 million to Indiana University over five years to expand clinical trial access and create an AI-enabled clinical trial infrastructure focused on Alzheimer's disease (search), diabetes (search), cancer (search), and cell and gene therapy.
The partnership aims to enhance clinical trial design, improve patient recruitment, and boost operational efficiency while leveraging IU Health's extensive provider network and expanding to additional health systems across Indiana.
The collaboration will accelerate access to neurological health resources with an initial focus on Alzheimer's disease (search), building on IU's neuroscience strengths and Lilly's global leadership in Alzheimer's innovation.
Eli Lilly and Company has announced a five-year, $40 million commitment to Indiana University aimed at transforming clinical trial infrastructure and expanding patient access to innovative treatments across the state. The partnership, formalized through an agreement signed by IU President Pamela Whitten and Lilly CEO David Ricks, focuses on creating an AI-enabled clinical trial system targeting Alzheimer's disease (search), diabetes (search), cancer (search), and cell and gene therapy.
AI-Powered Clinical Trial Innovation
The collaboration centers on developing what the partners describe as a "best-in-class, AI-enabled clinical trial infrastructure and operating model" focused on chronically prevalent diseases and oncology. The initiative aims to enhance clinical trial design, improve patient recruitment, and boost operational efficiency through advanced technological integration.
"Indiana has everything it takes to build a best-in-class system for clinical trial innovation: world-leading science, statewide health systems that reach patients where they are and a community that believes in turning discovery into better care," said David A. Ricks, chair and CEO of Lilly. "Partnering with IU under Pam Whitten's leadership, we can accelerate progress by removing barriers, enrolling patients faster and delivering life-changing medicines sooner."
The partnership will initially leverage IU Health's extensive provider and patient network before expanding to additional health systems across Indiana. This approach is designed to accelerate the translation of discovery into new therapies while strengthening Indiana's position in patient-centered clinical research.
Focus on Neurological Health and Alzheimer's Disease
A key component of the partnership involves accelerating access to neurological health resources for patients across Indiana, with an initial focus on Alzheimer's disease (search). The collaboration builds on IU's established strengths in neuroscience and clinical research, combined with Lilly's global leadership in Alzheimer's innovation.
The partnership aims to explore new approaches to diagnostics, treatment, and patient and family engagement in neurological conditions. This focus aligns with both organizations' research priorities and addresses significant unmet medical needs in the state.
Workforce Development and Talent Pipeline
The agreement includes provisions for cultivating a pipeline of skilled, diverse, and job-ready talent to meet Lilly's evolving workforce needs and support Indiana's broader life sciences sector. IU and Lilly plan to co-develop programs that will upskill current professionals and prepare IU students for careers in biotechnology, pharmaceutical research, and clinical innovation.
Through the partnership, students and researchers will gain real-world experience within Lilly's research, development, and manufacturing environments, creating a direct pathway from academic training to industry careers.
Economic Impact and Industry Growth
The partnership is positioned to fuel growth in Indiana's $99 billion life sciences industry by combining IU's research and clinical expertise with Lilly's leadership in biopharmaceutical innovation and manufacturing. The collaboration represents what officials describe as a new model for academic-industry partnerships focused on real-world outcomes.
"This agreement marks a new chapter for Indiana University and how we work with industry partners — moving with speed, purpose and a focus on real-world outcomes," said Pamela Whitten, president of Indiana University. "Together with Lilly, we're investing in Indiana's innovation ecosystem, building a platform that advances cutting-edge research and care and preparing students to lead in tomorrow's industries."
Implementation and Leadership
The IU portion of the partnership will be led by the IU Launch Accelerator for Biosciences (search) (IU LAB), which serves as the university's central engine for academic-industry collaboration. The initiative builds on significant recent investments in bioscience expertise and clinical trial delivery capabilities.
"This expanded partnership marks an exciting step forward for IU and how we engage with partners in mutually beneficial ways," said IU LAB President and CEO David Rosenberg. "Together, IU and Lilly will build the research capacity, talent and infrastructure that will accelerate scientific discovery, advance the care of Hoosiers, drive economic growth and solidify Indiana's position as a national leader in the life sciences."
The agreement represents the initial phase of what both organizations are prepared to expand as early projects demonstrate success, building on existing IU-Lilly collaborations while providing a structure for future projects that support both organizations' research priorities and Indiana's life sciences industry needs.